[ad_1]
BANGKOK, THAILAND – January 24, 2021 – Regenerative Medication Co., Ltd. (ReGenMed) are the main biomedicine specialists of superior integrative, anti-aging and regenerative healthcare merchandise targeted within the South East Asian market. The corporate is proud to announce that their pharmaceutical grade NAD+ product, known as “InfiNADi NAD+ Anti-Getting old Resolution”, is the primary FDA-approved product of its type. Having launched in 2019, the product was accredited by the Thailand FDA in October 2021. InfiNADi NAD+ is the #1 promoting and most trusted NAD+ utilized by high hospitals and clinics all through the area.
“We’re proud to be the primary FDA accredited NAD+ product in Asia. The approval additional confirms the standard and security of our InfiNADi NAD+ product which now will be prescribed with a good increased stage of confidence by our companion medical practitioners and hospitals.” – Narin Apichairuk, President
The Energy of NAD+
Because of well-liked analysis by famend Dr. David Sinclair of Harvard College, it’s recognized that enhancing ranges of the coenzyme, nicotinamide adenine dinucleotide, also called NAD+, can assist reverse indicators of getting older. This essential co-enzyme, known as “The Fountain of Youth Molecule,” is present in each cell of the physique and is concerned in lots of of metabolic processes. NAD+ has two common units of reactions within the human physique: serving to flip vitamins into vitality as a key participant in metabolism and dealing as a helper molecule for proteins that regulate different mobile capabilities. These processes are extremely essential, sadly, NAD+ ranges decline by over 50% by the age of 40, therefore the necessity to improve NAD+ ranges to take care of optimum bodily capabilities.
NAD+ remedy is quickly gaining momentum in each the anti-aging and medical area. ReGenMed maintains their market chief place as a trusted companion to assist and nurture pioneering developments that medical practitioners can use to implement remedies inside the upcoming area of regenerative drugs. That is the only focus of the corporate for over a decade.
“Our firm has been offering biomedicines to the area for over 15 years and could be very enthusiastic about regulatory approvals on this area. It offers each entry to our companions and medical suppliers, in addition to a stage of belief with the medical area that helps sturdy affected person care choices for our InfiNADi NAD+ providing.” – Brian Dardzinski, M.Sc., Director
As they continue to be dedicated to being revolutionary leaders within the area of anti-aging and regenerative medicine, the corporate appears ahead to launching extra superior merchandise in 2022. ReGenMed’s long-term imaginative and prescient evokes their expansive product developments that they give the impression of being to introduce to the area and past.
ABOUT Regenerative Medication Co., Ltd.
Impressed by cutting-edge innovation, Regenerative Medicine Co., Ltd. (ReGenMed) are the main biomedicine specialists of superior integrative, anti-aging and regenerative healthcare merchandise. Targeted on the South East Asian area, the corporate strives to make the inaccessible, accessible to medical practitioners round Asia. The corporate manufactures and distributes superior biomedicine options. InfiNADi NAD+ is the primary pharmaceutical grade, FDA-approved NAD+ launched in SE Asia.
Media Contact
Emmie Noe (Communications Supervisor)
Electronic mail: [email protected]
Telephone: + 66 92-719-7070
Net: www.regenmedasia.com
Media Contact
Firm Title: Regenerative Medication Co., Ltd.
Contact Particular person: Emmie Noe (Communications Supervisor)
Electronic mail: Send Email
Telephone: + 66 92-719-7070
Metropolis: Bangkok
Nation: Thailand
Web site: https://www.regenmedasia.com/
[ad_2]
Source link
